Soft Tissue Tumors (eBook)
XVII, 823 Seiten
Springer International Publishing (Verlag)
978-3-030-58710-9 (ISBN)
The 'world' of soft tissue sarcomas is a highly complex one, due to the large range of tumor types, each of which is characterized by specific features in terms of its epidemiology, pathology diagnosis, clinical behavior, therapy and biomarker pattern (of both diagnostic and therapeutic value). This book offers a practical, clearly structured reference guide, covering all of these aspects for each soft tissue tumor. Thanks to the consistent and user-friendly format, readers can quickly and easily find the information they need; in addition, up-to-date and authoritative literature information helps them to pursue further research.
Overall, this book offers professionals and residents in the fields of oncology, surgery, and pathology an essential guide for study, review, and everyday clinical practice.
Prof. Mocellin specialized in General Surgery in Padua in 1998, and received his Ph.D. in Oncology and Surgical Oncology from the University of Padua, Italy, in 2004.
Currently he is a Surgical Oncologist at the Melanoma and Sarcoma Unit of the Istituto Oncologico Veneto - Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS) in Padua, and a Professor of Surgery at the Department of Surgery Oncology and Gastroenterology (DiSCOG), University of Padua, Italy.
Since 2000, he authored more than 195 scientific articles published in international peer-reviewed medical journals, with a total impact factor of more than 1200, more than 9000 citations and an H-index equal to 52.
He is a member of the editorial board of several international peer-reviewed medical journals, and is an editor for the Cochrane Collaboration (the world's leading organization for medical meta-analysis).
Preface 6
Contents 8
Part I: Basics on Soft Tissue Tumors 17
1: Definition 18
Suggested Readings 19
2: Epidemiology and Presentation 20
Suggested Readings 24
3: Etiology and Predisposition 25
Suggested Readings 29
4: Pathology 30
Suggested Readings 37
5: Biomarkers 38
Suggested Readings 38
6: Prognosis 40
Suggested Readings 45
7: Therapy 46
Surgery 46
Radiotherapy 49
Chemotherapy 51
Target Therapy 55
Immunotherapy 56
Suggested Readings 57
Part II: Soft Tissue Tumors 61
8: Acoustic Neuroma 62
Definition 62
Epidemiology and Presentation 62
Etiology and Predisposition 63
Pathology 64
Biomarkers 64
Prognosis 64
Therapy 65
Suggested Readings 65
9: Acquired Digital Fibrokeratoma 66
Definition 66
Epidemiology and Presentation 66
Pathology 66
Biomarkers 67
Prognosis 67
Therapy 67
Suggested Readings 67
10: Acral Fibromyxoma 68
Definition 68
Epidemiology and Presentation 68
Pathology 68
Biomarkers 69
Prognosis 69
Therapy 69
Suggested Readings 69
11: Adult Fibrosarcoma 70
Definition 70
Epidemiology and Presentation 70
Pathology 70
Biomarkers 71
Prognosis 71
Therapy 71
Suggested Readings 72
12: Adult Rhabdomyoma 73
Definition 73
Epidemiology and Presentation 73
Pathology 73
Biomarkers 74
Prognosis 74
Therapy 74
13: Alveolar Rhabdomyosarcoma 75
Definition 75
Epidemiology and Presentation 75
Etiology and Predisposition 75
Pathology 76
Biomarkers 76
Prognosis 77
Therapy 77
Suggested Readings 77
14: Alveolar Soft Part Sarcoma 78
Definition 78
Epidemiology and Presentation 78
Pathology 78
Biomarkers 79
Prognosis 79
Therapy 80
Suggested Readings 81
15: Anastomosing Hemangioma 82
Definition 82
Epidemiology and Presentation 82
Pathology 82
Biomarkers 83
Prognosis 83
Therapy 83
Suggested Readings 83
16: Aneurysmal Fibrous Histiocytoma 84
Definition 84
Epidemiology and Presentation 84
Pathology 84
Biomarkers 85
Prognosis 85
Therapy 85
Suggested Readings 85
17: Angiofibroma 86
18: Angiofibroma of Soft Tissue 87
Definition 87
Epidemiology and Presentation 87
Pathology 87
Biomarkers 88
Prognosis 88
Therapy 88
Suggested Readings 89
19: Angiokeratoma 90
Definition 90
Epidemiology and Presentation 90
Pathology 90
Biomarkers 91
Prognosis 91
Therapy 91
Suggested Readings 91
20: Angioleiomyoma 92
Definition 92
Epidemiology and Presentation 92
Etiology and Predisposition 92
Pathology 93
Biomarkers 93
Prognosis 93
Therapy 93
Suggested Readings 93
21: Angiolipoma 94
Definition 94
Epidemiology and Presentation 94
Etiology and Predisposition 94
Pathology 95
Biomarkers 95
Prognosis 95
Therapy 95
Suggested Readings 95
22: Angiomatoid Fibrous Histiocytoma 96
Definition 96
Epidemiology and Presentation 96
Pathology 96
Biomarkers 97
Prognosis 98
Therapy 98
Suggested Readings 98
23: Angiomyofibroblastoma 99
Definition 99
Epidemiology and Presentation 99
Pathology 99
Biomarkers 100
Prognosis 100
Therapy 100
Suggested Readings 100
24: Angiomyolipoma 101
Definition 101
Epidemiology and Presentation 101
Etiology and Predisposition 101
Pathology 102
Biomarkers 102
Prognosis 103
Therapy 103
Suggested Readings 103
25: Angiosarcoma 104
Definition 104
Epidemiology and Presentation 104
Etiology and Predisposition 104
Pathology 105
Biomarkers 106
Prognosis 106
Therapy 106
Suggested Readings 107
26: Angiomatosis 109
Definition 109
Epidemiology and Presentation 109
Etiology and Predisposition 110
Pathology 110
Biomarkers 111
Prognosis 111
Therapy 111
Suggested Readings 111
27: Angiomyxoma 112
28: Arteriovenous Malformation Hemangioma 113
Definition 113
Epidemiology and Presentation 113
Etiology and Predisposition 114
Pathology 114
Biomarkers 114
Prognosis 114
Therapy 114
Suggested Readings 115
29: Atypical Fibrous Histiocytoma 116
Definition 116
Epidemiology and Presentation 116
Pathology 116
Biomarkers 117
Prognosis 117
Therapy 117
Suggested Readings 117
30: Atypical Fibroxanthoma 118
Definition 118
Epidemiology and Presentation 118
Etiology and Predisposition 119
Pathology 119
Biomarkers 119
Prognosis 119
Therapy 120
Suggested Readings 120
31: Atypical Lipomatous Tumor 121
32: Atypical Vascular Lesion 122
Definition 122
Epidemiology and Presentation 122
Etiology and Predisposition 122
Pathology 122
Biomarkers 123
Prognosis 123
Therapy 123
Suggested Readings 123
33: BCOR-Rearranged Sarcoma 124
34: Benign Fibrous Histiocytoma 125
Definition 125
Epidemiology and Presentation 125
Pathology 126
Biomarkers 126
Prognosis 127
Therapy 127
Suggested Readings 127
35: Benign Metastasizing Leiomyoma 129
Definition 129
Epidemiology and Presentation 129
Etiology and Predisposition 129
Pathology 130
Biomarkers 130
Prognosis 130
Therapy 130
Suggested Readings 130
36: Benign Triton Tumor 131
Definition 131
Epidemiology and Presentation 131
Pathology 131
Prognosis 132
Therapy 132
Suggested Readings 132
37: Biphenotypic Sinonasal Sarcoma 133
Definition 133
Epidemiology and Presentation 133
Pathology 133
Biomarkers 134
Prognosis 134
Therapy 134
Suggested Readings 134
38: Bladder Soft Tissue Tumors 136
39: Breast Angiosarcoma 137
Definition 137
Epidemiology and Presentation 137
Etiology and Predisposition 137
Pathology 138
Biomarkers 138
Prognosis 138
Therapy 139
Suggested Readings 139
40: Breast Phyllodes Tumor 140
Definition 140
Epidemiology and Presentation 140
Pathology 140
Biomarkers 141
Prognosis 141
Therapy 141
Suggested Readings 142
41: Breast Soft Tissue Tumors 143
42: Calcifying Aponeurotic Fibroma 144
Definition 144
Epidemiology and Presentation 144
Pathology 144
Biomarkers 145
Prognosis 145
Therapy 145
Suggested Readings 145
43: Calcifying Fibrous Tumor 146
Definition 146
Epidemiology and Presentation 146
Etiology and Predisposition 146
Pathology 147
Biomarkers 147
Prognosis 147
Therapy 147
Suggested Readings 147
44: Cardiac Soft Tissue Tumors 148
45: Cardiac Myxoma 150
Definition 150
Epidemiology and Presentation 150
Etiology and Predisposition 150
Pathology 151
Biomarkers 151
Prognosis 151
Therapy 151
Suggested Readings 151
46: Cardiac Rhabdomyoma 152
Definition 152
Epidemiology and Presentation 152
Etiology and Predisposition 152
Pathology 153
Biomarkers 153
Prognosis 153
Therapy 153
Suggested Readings 154
47: Cellular Angiofibroma 155
Definition 155
Epidemiology and Presentation 155
Pathology 155
Biomarkers 156
Prognosis 156
Therapy 156
Suggested Readings 156
48: Cellular Fibrous Histiocytoma 157
Definition 157
Epidemiology and Presentation 157
Pathology 157
Biomarkers 158
Prognosis 158
Therapy 158
Suggested Readings 158
49: Cherry Hemangioma 159
Definition 159
Epidemiology and Presentation 159
Pathology 159
Biomarkers 159
Prognosis 160
Therapy 160
Suggested Reading 160
50: Chondroid Lipoma 161
Definition 161
Epidemiology and Presentation 161
Pathology 161
Biomarkers 162
Prognosis 162
Therapy 162
Suggested Readings 162
51: CIC-Rearranged Sarcoma 163
52: Clear Cell Sarcoma 164
Definition 164
Epidemiology and Presentation 164
Pathology 164
Biomarkers 165
Prognosis 165
Therapy 166
Suggested Readings 166
53: Clear Cell Sugar Tumor 168
Definition 168
Epidemiology and Presentation 168
Etiology and Predisposition 168
Pathology 169
Biomarkers 169
Prognosis 169
Therapy 169
Suggested Readings 169
54: Composite Hemangioendothelioma 170
Definition 170
Epidemiology and Presentation 170
Pathology 170
Prognosis 170
Therapy 171
Suggested Readings 171
55: Congenital Hemangioma 172
Definition 172
Epidemiology and Presentation 172
Pathology 173
Biomarkers 173
Prognosis 173
Therapy 174
Suggested Readings 174
56: Congenital Mesoblastic Nephroma 175
Definition 175
Epidemiology and Presentation 175
Pathology 176
Biomarkers 176
Prognosis 177
Therapy 177
Suggested Readings 177
57: Cutaneous Angiofibroma 179
Definition 179
Epidemiology and Presentation 179
Etiology and Predisposition 180
Pathology 180
Biomarkers 181
Prognosis 182
Therapy 182
Suggested Readings 182
58: Cutaneous Angiosarcoma 183
Suggested Readings 183
59: Cutaneous Epithelioid Angiomatous Nodule 184
Definition 184
Epidemiology and Presentation 184
Pathology 184
Biomarkers 185
Prognosis 185
Therapy 185
Suggested Readings 186
60: Cutaneous Fibroepithelial Polyp 187
Definition 187
Epidemiology and Presentation 187
Etiology and Predisposition 187
Pathology 188
Prognosis 188
Therapy 188
Suggested Readings 188
61: Cutaneous Leiomyoma 189
Definition 189
Epidemiology and Presentation 189
Etiology and Predisposition 190
Pathology 190
Biomarkers 191
Prognosis 191
Therapy 191
Suggested Readings 191
62: Cutaneous Leiomyosarcoma 192
Definition 192
Epidemiology and Presentation 192
Pathology 192
Biomarkers 193
Prognosis 193
Therapy 193
Suggested Readings 194
63: Dedifferentiated Liposarcoma 195
Definition 195
Epidemiology and Presentation 195
Pathology 195
Biomarkers 196
Prognosis 197
Therapy 197
Suggested Readings 198
64: Deep Angiomyxoma 199
Definition 199
Epidemiology and Presentation 199
Pathology 199
Biomarkers 200
Prognosis 200
Therapy 200
Suggested Readings 200
65: Dermal Nerve Sheath Myxoma 202
Definition 202
Epidemiology and Presentation 202
Pathology 202
Biomarkers 203
Prognosis 203
Therapy 204
Suggested Readings 204
66: Dermatofibroma 205
67: Dermatofibrosarcoma Protuberans 206
Definition 206
Epidemiology and Presentation 206
Etiology and Predisposition 207
Pathology 207
Biomarkers 208
Prognosis 209
Therapy 209
Suggested Readings 210
68: Dermatomyofibroma 211
Definition 211
Epidemiology and Presentation 211
Pathology 211
Biomarkers 212
Prognosis 212
Therapy 212
Suggested Readings 212
69: Desmoid-Type Fibromatosis 213
Definition 213
Epidemiology and Presentation 213
Etiology and Predisposition 215
Pathology 215
Biomarkers 216
Prognosis 217
Therapy 217
Suggested Readings 219
70: Desmoplastic Fibroblastoma 220
Definition 220
Epidemiology and Presentation 220
Pathology 220
Biomarkers 221
Prognosis 221
Therapy 221
Suggested Readings 221
71: Desmoplastic Small Round Cell Tumor 222
Definition 222
Epidemiology and Presentation 222
Pathology 222
Biomarkers 223
Prognosis 223
Therapy 223
Suggested Readings 223
72: Diffuse Pulmonary Lymphangiomatosis 225
Definition 225
Epidemiology and Presentation 225
Pathology 225
Biomarkers 225
Prognosis 226
Therapy 226
Suggested Readings 226
73: Diffuse Tenosynovial Giant Cell Tumor 227
Definition 227
Epidemiology and Presentation 227
Etiology and Predisposition 228
Pathology 228
Biomarkers 228
Prognosis 229
Therapy 229
Suggested Readings 229
74: Digestive System Soft Tissue Tumors 231
75: EBV-Associated Smooth Muscle Tumor 233
Definition 233
Epidemiology and Presentation 233
Etiology and Predisposition 233
Pathology 233
Biomarkers 234
Prognosis 234
Therapy 234
Suggested Readings 234
76: Disseminated Peritoneal Leiomyomatosis 235
Definition 235
Epidemiology and Presentation 235
Etiology and Predisposition 235
Pathology 235
Biomarkers 236
Prognosis 236
Therapy 236
Suggested Readings 236
77: Ectomesenchymoma 237
Definition 237
Epidemiology and Presentation 237
Pathology 237
Biomarkers 238
Prognosis 238
Therapy 238
Suggested Readings 238
78: Ectopic Hamartomatous Thymoma 239
Definition 239
Epidemiology and Presentation 239
Pathology 239
Biomarkers 239
Prognosis 239
Therapy 240
Suggested Readings 240
79: Ectopic Meningioma 241
Definition 241
Epidemiology and Presentation 241
Pathology 242
Biomarkers 242
Prognosis 242
Therapy 243
Suggested Readings 243
80: Elastofibroma 245
Definition 245
Epidemiology and Presentation 245
Pathology 245
Biomarkers 246
Prognosis 246
Therapy 246
Suggested Readings 246
81: Embryonal Rhabdomyosarcoma 247
Definition 247
Epidemiology and Presentation 247
Etiology and Predisposition 248
Pathology 248
Biomarkers 249
Prognosis 249
Therapy 250
Suggested Readings 250
82: Endometrial Stromal Sarcoma 251
Definition 251
Epidemiology and Presentation 251
Pathology 251
Biomarkers 252
Prognosis 253
Therapy 254
Suggested Readings 254
83: Epithelioid Fibrous Histiocytoma 255
Definition 255
Epidemiology and Presentation 255
Pathology 255
Biomarkers 256
Prognosis 256
Therapy 256
Suggested Readings 257
84: Epithelioid Hemangioendothelioma 258
Definition 258
Epidemiology and Presentation 258
Pathology 258
Biomarkers 259
Prognosis 259
Therapy 260
Suggested Readings 260
85: Epithelioid Hemangioma 261
Definition 261
Epidemiology and Presentation 261
Pathology 261
Biomarkers 262
Prognosis 262
Therapy 262
Suggested Readings 262
86: Epithelioid Sarcoma 263
Definition 263
Epidemiology and Presentation 263
Pathology 264
Biomarkers 264
Prognosis 265
Therapy 265
Suggested Readings 266
87: Esophageal Leiomyoma 267
Definition 267
Epidemiology and Presentation 267
Pathology 268
Biomarkers 268
Prognosis 268
Therapy 268
Suggested Readings 269
88: Ewing-Like Sarcomas 270
Definition 270
Non-ETS-Rearranged Ewing-Like Sarcoma 271
CIC-Rearranged Ewing-Like Sarcoma 271
BCOR-Rearranged Ewing-Like Sarcoma 272
Adamantinoma-Like Ewing Sarcoma 273
Askin Tumor 273
Peripheral Primary Neuroectodermal Tumor (pPNET) 273
Suggested Readings 273
89: Extrarenal Rhabdoid Tumor 275
Definition 275
Epidemiology and Presentation 275
Etiology and Predisposition 275
Pathology 276
Biomarkers 276
Prognosis 277
Therapy 277
Suggested Readings 277
90: Extraskeletal Aneurysmal Bone Cyst 278
Definition 278
Epidemiology and Presentation 278
Pathology 278
Biomarkers 279
Prognosis 279
Therapy 279
Suggested Readings 279
91: Extraskeletal Chondroma 280
Definition 280
Epidemiology and Presentation 280
Pathology 280
Prognosis 281
Therapy 281
Suggested Readings 281
92: Extraskeletal Chordoma 282
Definition 282
Epidemiology and Presentation 282
Etiology and Predisposition 283
Pathology 283
Biomarkers 284
Prognosis 284
Therapy 284
Suggested Readings 285
93: Extraskeletal Ewing Sarcoma 286
Definition 286
Epidemiology and Presentation 286
Pathology 286
Biomarkers 287
Prognosis 289
Therapy 289
Suggested Readings 290
94: Extraskeletal Myxoid Chondrosarcoma 292
Definition 292
Epidemiology and Presentation 292
Pathology 292
Biomarkers 293
Prognosis 293
Therapy 293
Suggested Readings 294
95: Extraskeletal Osteosarcoma 295
Definition 295
Epidemiology and Presentation 295
Etiology and Predisposition 296
Pathology 296
Biomarkers 296
Prognosis 296
Therapy 297
Suggested Readings 297
96: Fetal Rhabdomyoma 298
Definition 298
Epidemiology and Presentation 298
Etiology and Predisposition 298
Pathology 299
Biomarkers 299
Prognosis 299
Therapy 300
Suggested Readings 300
97: Fibroma 301
98: Fibroma of Tendon Sheath 302
Definition 302
Epidemiology and Presentation 302
Pathology 302
Biomarkers 302
Prognosis 302
Therapy 303
Suggested Reading 303
99: Fibromatosis 304
100: Fibromatosis Colli 305
Definition 305
Epidemiology and Presentation 305
Pathology 305
Biomarkers 306
Prognosis 306
Therapy 306
Suggested Readings 306
101: Fibro-Osseous Pseudotumor of Digits 307
102: Fibrosarcoma 308
103: Fibrous Hamartoma of Infancy 309
Definition 309
Epidemiology and Presentation 309
Pathology 309
Biomarkers 309
Prognosis 310
Therapy 310
Suggested Readings 310
104: Fibrous Histiocytoma 311
105: Gardner Fibroma 312
Definition 312
Epidemiology and Presentation 312
Etiology and Predisposition 312
Pathology 313
Biomarkers 313
Prognosis 313
Therapy 313
Suggested Readings 314
106: Gastrointestinal Clear Cell Sarcoma 315
Definition 315
Epidemiology and Presentation 315
Pathology 315
Biomarkers 316
Prognosis 316
Therapy 316
Suggested Readings 316
107: Gastrointestinal Soft Tissue Tumors 318
108: Gastrointestinal Stromal Tumor (GIST) 319
Definition 319
Epidemiology and Presentation 319
Etiology and Predisposition 320
Pathology 321
Biomarkers 322
Prognosis 323
Therapy 324
Suggested Readings 329
109: Genital Rhabdomyoma 332
Definition 332
Epidemiology and Presentation 332
Pathology 332
Biomarkers 333
Prognosis 333
Therapy 333
Suggested Readings 333
110: Giant Cell Fibroblastoma 334
Definition 334
Epidemiology and Presentation 334
Pathology 334
Biomarkers 335
Prognosis 335
Therapy 335
Suggested Readings 335
111: Giant Cell Tumor 336
Definition 336
Epidemiology and Presentation 336
Pathology 336
Biomarkers 337
Prognosis 337
Therapy 337
Suggested Readings 338
112: Glomeruloid Hemangioma 339
Definition 339
Epidemiology and Presentation 339
Etiology and Predisposition 339
Pathology 339
Biomarkers 340
Prognosis 340
Therapy 340
Suggested Reading 340
113: Glomus Tumor 341
Definition 341
Epidemiology and Presentation 341
Etiology and Predisposition 341
Pathology 342
Biomarkers 343
Prognosis 343
Therapy 343
Suggested Readings 343
114: Granular Cell Tumor 345
Definition 345
Epidemiology and Presentation 345
Etiology and Predisposition 345
Pathology 346
Biomarkers 347
Prognosis 347
Therapy 347
Suggested Readings 347
115: Hemangioblastoma 349
Definition 349
Epidemiology and Presentation 349
Etiology and Predisposition 349
Pathology 350
Biomarkers 350
Prognosis 350
Therapy 350
Suggested Readings 350
116: Hemangioendothelioma 351
117: Hemangioma 352
Definition 352
Epidemiology and Presentation 353
Pathology 353
Biomarkers 353
Prognosis 353
Therapy 354
118: Hemosiderotic Fibrolipomatous Tumor 355
Definition 355
Epidemiology and Presentation 355
Pathology 355
Biomarkers 355
Prognosis 356
Therapy 356
Suggested Readings 356
119: Hepatic Angiosarcoma 357
Definition 357
Epidemiology and Presentation 357
Etiology and Predisposition 358
Pathology 358
Prognosis 358
Therapy 358
Suggested Readings 358
120: Hepatic Calcifying Nested Stromal Epithelial Tumor 359
Definition 359
Epidemiology and Presentation 359
Pathology 360
Biomarkers 360
Prognosis 360
Therapy 360
Suggested Readings 360
121: Hepatic Embryonal Sarcoma 362
Definition 362
Epidemiology and Presentation 362
Pathology 362
Biomarkers 363
Prognosis 363
Therapy 363
Suggested Readings 364
122: Hepatic Epithelioid Hemangioendothelioma 365
Definition 365
Epidemiology and Presentation 365
Pathology 365
Biomarkers 366
Prognosis 366
Therapy 367
Suggested Readings 367
123: Hepatic Hemangioma 368
Definition 368
Epidemiology and Presentation 368
Pathology 369
Biomarkers 369
Prognosis 369
Therapy 370
Suggested Readings 370
124: Hepatic Mesenchymal Hamartoma 371
Definition 371
Epidemiology and Presentation 371
Etiology and Predisposition 372
Pathology 372
Biomarkers 372
Prognosis 373
Therapy 373
Suggested Readings 373
125: Hibernoma 374
Definition 374
Epidemiology and Presentation 374
Pathology 374
Biomarkers 374
Prognosis 375
Therapy 375
Suggested Readings 375
126: High-Grade Endometrial Stromal Sarcoma 376
127: Hobnail Hemangioma 377
Definition 377
Epidemiology and Presentation 377
Pathology 377
Biomarkers 377
Prognosis 378
Therapy 378
Suggested Readings 378
128: Hybrid Nerve Sheath Tumor 379
Definition 379
Epidemiology and Presentation 379
Etiology and Predisposition 379
Pathology 379
Biomarkers 380
Prognosis 380
Therapy 380
Suggested Readings 380
129: Inclusion Body Fibromatosis 381
Definition 381
Epidemiology and Presentation 381
Pathology 381
Biomarkers 382
Prognosis 382
Therapy 382
Suggested Readings 382
130: Infantile Fibrosarcoma 383
Definition 383
Epidemiology and Presentation 383
Pathology 383
Biomarkers 384
Prognosis 384
Therapy 384
Suggested Readings 385
131: Infantile Hemangioma 386
Definition 386
Epidemiology and Presentation 386
Etiology and Predisposition 388
Pathology 388
Biomarkers 388
Prognosis 388
Therapy 388
Suggested Readings 389
132: Inflammatory Fibroid Polyp 390
Definition 390
Epidemiology and Presentation 390
Etiology and Predisposition 390
Pathology 391
Biomarkers 391
Prognosis 391
Therapy 391
Suggested Readings 391
133: Inflammatory Myofibroblastic Tumor 392
Definition 392
Epidemiology and Presentation 392
Pathology 393
Biomarkers 393
Prognosis 394
Therapy 394
Suggested Readings 394
134: Intimal Sarcoma 396
Definition 396
Epidemiology and Presentation 396
Pathology 396
Biomarkers 397
Prognosis 397
Therapy 397
Suggested Readings 397
135: Intramuscular Hemangioma 398
Definition 398
Epidemiology and Presentation 398
Pathology 398
Prognosis 399
Therapy 399
Suggested Readings 399
136: Intramuscular Myxoma 400
Definition 400
Epidemiology and Presentation 400
Pathology 400
Biomarkers 401
Prognosis 401
Therapy 401
Suggested Readings 401
137: Ischemic Fasciitis 402
Definition 402
Epidemiology and Presentation 402
Pathology 402
Biomarkers 403
Prognosis 403
Therapy 403
Suggested Readings 403
138: Juvenile Hyaline Fibromatosis 404
Definition 404
Epidemiology and Presentation 404
Etiology and Predisposition 405
Pathology 405
Biomarkers 405
Prognosis 405
Therapy 405
Suggested Readings 405
139: Juxta-Articular Myxoma 406
Definition 406
Epidemiology and Presentation 406
Pathology 406
Biomarkers 406
Prognosis 407
Therapy 407
Suggested Readings 407
140: Juxtaglomerular Cell Tumor 408
Definition 408
Epidemiology and Presentation 408
Pathology 408
Biomarkers 408
Prognosis 409
Therapy 409
Suggested Readings 409
141: Kaposiform Hemangioendothelioma 410
Definition 410
Epidemiology and Presentation 410
Pathology 410
Biomarkers 411
Prognosis 411
Therapy 411
Suggested Readings 411
142: Kaposi Sarcoma 412
Definition 412
Epidemiology and Presentation 412
Etiology and Predisposition 413
Pathology 413
Biomarkers 414
Prognosis 414
Therapy 415
Suggested Readings 415
143: Kidney Clear Cell Sarcoma 417
Definition 417
Epidemiology and Presentation 417
Pathology 417
Biomarkers 418
Prognosis 418
Therapy 418
Suggested Readings 419
144: Kidney Rhabdoid Tumor 420
145: Kidney Soft Tissue Tumors 421
146: Leiomyoma 422
147: Leiomyoma of Deep Tissue 423
Definition 423
Epidemiology and Presentation 423
Pathology 423
Biomarkers 424
Prognosis 424
Therapy 424
Suggested Readings 424
148: Leiomyosarcoma 425
Definition 425
Epidemiology and Presentation 425
Etiology and Predisposition 426
Pathology 426
Biomarkers 427
Prognosis 427
Therapy 428
Suggested Readings 428
149: Lipoblastoma 430
Definition 430
Epidemiology and Presentation 430
Pathology 430
Biomarkers 431
Prognosis 431
Therapy 431
Suggested Readings 431
150: Lipofibromatosis 432
Definition 432
Epidemiology and Presentation 432
Pathology 432
Biomarkers 433
Prognosis 433
Therapy 433
Suggested Readings 433
151: Lipofibromatosis-Like Neural Tumor 434
Definition 434
Epidemiology and Presentation 434
Pathology 434
Biomarkers 435
Prognosis 435
Therapy 435
Suggested Readings 436
152: Lipoma 437
Definition 437
Epidemiology and Presentation 437
Etiology and Predisposition 438
Pathology 439
Biomarkers 439
Prognosis 439
Therapy 439
Suggested Readings 440
153: Lipomatosis 441
Definition 441
Epidemiology and Presentation 442
Diagnosis 442
Biomarkers 443
Prognosis 443
Therapy 443
Suggested Readings 443
154: Lipomatosis of Nerve 445
Definition 445
Epidemiology and Presentation 445
Pathology 445
Therapy 445
Suggested Readings 446
155: Liposarcoma 447
Definition 447
Epidemiology and Presentation 447
Etiology and Predisposition 447
Pathology 448
Biomarkers 448
Prognosis 448
Suggested Readings 449
156: Littoral Cell Angioma 450
Definition 450
Epidemiology and Presentation 450
Pathology 450
Biomarkers 451
Prognosis 451
Therapy 451
Suggested Readings 451
157: Localized Tenosynovial Giant Cell Tumor 452
Definition 452
Epidemiology and Presentation 452
Pathology 452
Biomarkers 453
Prognosis 453
Therapy 453
Suggested Readings 453
158: Low-Grade Endometrial Stromal Sarcoma 454
159: Low-Grade Fibromyxoid Sarcoma 455
Definition 455
Epidemiology and Presentation 455
Pathology 455
Biomarkers 456
Prognosis 456
Therapy 457
Suggested Readings 457
160: Low-Grade Myofibroblastic Sarcoma 458
Definition 458
Epidemiology and Presentation 458
Pathology 458
Biomarkers 459
Prognosis 459
Therapy 459
Suggested Readings 459
161: Lung Chondroma 461
Definition 461
Epidemiology and Presentation 461
Etiology and Predisposition 461
Pathology 462
Biomarkers 462
Prognosis 462
Therapy 462
Suggest Readings 462
162: Lung Soft Tissue Tumors 463
163: Lymphangioleiomyomatosis 464
Definition 464
Epidemiology and Presentation 464
Etiology and Predisposition 465
Pathology 465
Biomarkers 465
Prognosis 465
Therapy 465
Suggested Readings 466
164: Lymphangioma 467
Definition 467
Epidemiology and Presentation 467
Pathology 467
Biomarkers 468
Prognosis 468
Therapy 468
Suggested Readings 468
165: Malignant Fibrous Histiocytoma 469
166: Malignant Granular Cell Tumor 470
Definition 470
Epidemiology and Presentation 470
Pathology 470
Biomarkers 471
Prognosis 471
Therapy 471
Suggested Readings 471
167: Malignant Peripheral Nerve Sheath Tumor 472
Definition 472
Epidemiology and Presentation 472
Etiology and Predisposition 472
Pathology 473
Biomarkers 474
Prognosis 474
Therapy 475
Suggested Readings 475
168: Malignant Triton Tumor 477
168.1 Definition 477
Suggested Readings 477
169: Mediastinum Soft Tissue Tumors 478
170: Melanotic Schwannoma 479
Definition 479
Epidemiology and Presentation 479
Etiology and Predisposition 479
Pathology 480
Biomarkers 480
Prognosis 480
Therapy 481
Suggested Readings 481
171: Mesenchymal Chondrosarcoma 482
Definition 482
Epidemiology and Presentation 482
Pathology 482
Biomarkers 483
Prognosis 483
Therapy 484
Suggested Readings 484
172: Mesenchymoma 485
Definition 485
Suggested Readings 485
173: Microvenular Hemangioma 486
Definition 486
Epidemiology and Presentation 486
Pathology 486
Biomarkers 487
Prognosis 487
Therapy 487
Suggested Readings 487
174: Myelolipoma 488
Definition 488
Epidemiology and Presentation 488
Etiology and Predisposition 488
Pathology 489
Biomarkers 489
Prognosis 489
Therapy 489
Suggested Readings 489
175: Myoepithelioma 490
Definition 490
Epidemiology and Predisposition 490
Pathology 491
Biomarkers 491
Prognosis 492
Therapy 492
Suggested Readings 492
176: Myofibroblastoma 493
Definition 493
Epidemiology and Presentation 493
Pathology 493
Biomarkers 494
Prognosis 494
Therapy 494
Suggested Readings 494
177: Myofibroma 495
Definition 495
Epidemiology and Presentation 495
Etiology and Predisposition 495
Pathology 496
Biomarkers 496
Prognosis 497
Therapy 497
Suggested Readings 497
178: Myolipoma of Soft Tissue 498
Definition 498
Epidemiology and Presentation 498
Pathology 498
Biomarkers 498
Prognosis 498
Therapy 499
Suggested Readings 499
179: Myopericytoma 500
Definition 500
Epidemiology and Presentation 500
Pathology 500
Biomarkers 501
Prognosis 502
Therapy 502
Suggested Readings 502
180: Myositis Ossificans 503
Definition 503
Epidemiology and Presentation 503
Pathology 504
Biomarkers 504
Prognosis 504
Therapy 504
Suggested Readings 505
181: Myxofibrosarcoma 506
Definition 506
Epidemiology and Presentation 506
Pathology 506
Biomarkers 507
Prognosis 508
Therapy 508
Suggested Readings 508
182: Myxoid/Round Cell Liposarcoma 509
Definition 509
Epidemiology and Presentation 509
Pathology 509
Biomarkers 510
Prognosis 511
Therapy 511
Suggested Readings 512
183: Myxoinflammatory Fibroblastic Sarcoma 513
Definition 513
Epidemiology and Presentation 513
Pathology 513
Biomarkers 514
Prognosis 515
Therapy 515
Suggested Readings 515
184: Myxoma 516
185: Nasal Glial Heterotopia 517
Definition 517
Epidemiology and Presentation 517
Pathology 517
Biomarkers 518
Prognosis 518
Therapy 518
Suggested Reading 518
186: Nasopharyngeal Angiofibroma 519
Definition 519
Epidemiology and Presentation 519
Pathology 519
Biomarkers 520
Prognosis 520
Therapy 520
Suggested Readings 520
187: Neurofibroma 522
Definition 522
Epidemiology and Presentation 522
Etiology and Predisposition 523
Pathology 525
Biomarkers 527
Prognosis 527
Therapy 527
Suggested Readings 528
188: Neuroma 530
Definition 530
Epidemiology and Presentation 530
Etiology and Predisposition 531
Pathology 531
Therapy 531
Suggested Readings 531
189: Neurothekeoma 532
Definition 532
Epidemiology and Presentation 532
Pathology 532
Biomarkers 533
Prognosis 533
Therapy 533
Suggested Readings 533
190: Nevus Lipomatosus Superficialis 534
Definition 534
Epidemiology and Presentation 534
Pathology 535
Biomarkers 535
Prognosis 535
Therapy 535
Suggested Readings 535
191: Nodular Fasciitis 536
Definition 536
Epidemiology and Presentation 536
Pathology 536
Biomarkers 537
Prognosis 537
Therapy 538
Suggested Readings 538
192: Nuchal-Type Fibroma 539
Definition 539
Epidemiology and Presentation 539
Etiology and Predisposition 539
Pathology 539
Biomarkers 540
Prognosis 540
Therapy 540
Suggested Readings 540
193: Ossifying Fibromyxoid Tumor 541
Definition 541
Epidemiology and Presentation 541
Pathology 541
Biomarkers 541
Prognosis 542
Therapy 542
Suggested Readings 542
194: Ovarian Fibroma 543
Definition 543
Epidemiology and Presentation 543
Etiology and Predisposition 544
Pathology 544
Biomarkers 544
Prognosis 544
Therapy 545
Suggested Readings 545
195: Ovarian Sclerosing Stromal Tumor 546
Definition 546
Epidemiology and Presentation 546
Pathology 546
Biomarkers 547
Prognosis 547
Therapy 547
Suggested Readings 548
196: Palmar/Plantar Fibromatosis 549
Definition 549
Epidemiology and Presentation 549
Etiology and Predisposition 550
Pathology 550
Biomarkers 550
Prognosis 551
Therapy 551
Suggested Readings 551
197: Papillary Intralymphatic Angioendothelioma 552
Definition 552
Epidemiology and Presentation 552
Pathology 552
Biomarkers 552
Prognosis 553
Therapy 553
Suggested Readings 553
198: Perivascular Epithelioid Cell Tumor (PEComa) 554
Definition 554
Epidemiology and Presentation 554
Etiology and Predisposition 555
Pathology 555
Biomarkers 556
Prognosis 556
Therapy 557
Suggested Readings 557
199: Perineurioma 559
Definition 559
Epidemiology and Presentation 559
Pathology 559
Biomarkers 560
Prognosis 560
Therapy 560
Suggested Readings 560
200: Peripheral Primitive Neuroectodermal Tumor 561
Definition 561
Epidemiology and Presentation 561
Pathology 562
Biomarkers 562
Prognosis 562
Therapy 563
Suggested Readings 563
201: Phosphaturic Mesenchymal Tumor 564
Definition 564
Epidemiology and Presentation 564
Pathology 564
Biomarkers 565
Prognosis 565
Therapy 565
Suggested Readings 565
202: Pleomorphic Dermal Sarcoma 566
Definition 566
Epidemiology and Presentation 566
Pathology 566
Biomarkers 567
Prognosis 567
Therapy 567
Suggested Readings 567
203: Pleomorphic Fibroma 569
Definition 569
Epidemiology and Presentation 569
Pathology 569
Biomarkers 570
Prognosis 570
Therapy 570
Suggested Readings 571
204: Pleomorphic Hyalinizing Angiectatic Tumor 572
Definition 572
Epidemiology and Presentation 572
Pathology 572
Biomarkers 572
Prognosis 573
Therapy 573
Suggested Readings 573
205: Pleomorphic Lipoma 574
206: Pleomorphic Liposarcoma 575
Definition 575
Epidemiology and Presentation 575
Pathology 575
Biomarkers 576
Prognosis 576
Therapy 577
Suggested Readings 577
207: Pleomorphic Rhabdomyosarcoma 578
Definition 578
Epidemiology and Presentation 578
Pathology 578
Biomarkers 579
Prognosis 579
Therapy 579
Suggested Readings 579
208: Pleuropulmonary Blastoma 580
Definition 580
Etiology and Predisposition 580
Pathology 581
Biomarkers 581
Prognosis 582
Therapy 582
Suggested Readings 582
209: Plexiform Fibrohistiocytic Tumor 583
Definition 583
Epidemiology and Presentation 583
Pathology 583
Biomarkers 584
Prognosis 584
Therapy 584
Suggested Readings 584
210: Plexiform Fibromyxoma 585
Definition 585
Epidemiology and Presentation 585
Pathology 585
Biomarkers 586
Prognosis 586
Therapy 586
Suggested Readings 587
211: Primitive Myxoid Mesenchymal Tumor of Infancy 588
Definition 588
Epidemiology and Presentation 588
Pathology 588
Biomarkers 588
Prognosis 589
Therapy 589
Suggested Readings 589
212: Proliferative Fasciitis 590
Definition 590
Epidemiology and Presentation 590
Pathology 590
Biomarkers 591
Prognosis 591
Therapy 591
Suggested Readings 591
213: Proliferative Myositis 592
Definition 592
Epidemiology and Presentation 592
Pathology 592
Biomarkers 593
Prognosis 593
Therapy 593
Suggested Readings 593
214: Prostate Stromal Tumor of Uncertain Malignant Potential 594
Definition 594
Epidemiology and Presentation 594
Pathology 594
Biomarkers 595
Prognosis 595
Therapy 595
Suggested Readings 595
215: Prostate Soft Tissue Tumors 596
216: Prostate Stromal Sarcoma 598
Definition 598
Epidemiology and Presentation 598
Pathology 598
Biomarkers 599
Prognosis 599
Therapy 599
Suggested Readings 599
217: Pseudoangiomatous Stromal Hyperplasia 600
Definition 600
Epidemiology and Presentation 600
Pathology 600
Biomarkers 601
Prognosis 601
Therapy 601
Suggested Readings 601
218: Pseudomyogenic Hemangioendothelioma 602
Definition 602
Epidemiology and Presentation 602
Pathology 602
Biomarkers 603
Prognosis 603
Therapy 603
Suggested Readings 603
219: Pulmonary Myxoid Sarcoma 604
Definition 604
Epidemiology and Presentation 604
Etiology and Predisposition 604
Pathology 604
Biomarkers 605
Prognosis 605
Therapy 605
Suggested Readings 605
220: Pyogenic Granuloma 607
Definition 607
Epidemiology and Presentation 607
Pathology 607
Biomarkers 608
Prognosis 608
Therapy 608
Suggested Readings 608
221: Retiform Hemangioendothelioma 609
Definition 609
Epidemiology and Presentation 609
Pathology 609
Biomarkers 609
Prognosis 610
Therapy 610
Suggested Readings 610
222: Rhabdoid Tumor 611
Definition 611
Epidemiology and Presentation 611
Etiology and Predisposition 612
Pathology 613
Biomarkers 613
Prognosis 613
Therapy 614
Suggested Readings 614
223: Rhabdomyoma 615
224: Rhabdomyosarcoma 616
Definition 616
Epidemiology and Presentation 616
Etiology and Predisposition 617
Pathology 618
Biomarkers 618
Prognosis 619
Therapy 620
Suggested Readings 621
225: Schwannoma 622
Definition 622
Epidemiology and Presentation 622
Etiology and Predisposition 623
Pathology 625
Biomarkers 626
Prognosis 626
Therapy 626
Suggested Readings 627
226: Sclerosing Epithelioid Fibrosarcoma 628
Definition 628
Epidemiology and Presentation 628
Pathology 628
Biomarkers 629
Prognosis 630
Therapy 630
Suggested Readings 630
227: Sclerotic Fibroma 631
Definition 631
Epidemiology and Presentation 631
Etiology and Predisposition 631
Pathology 632
Biomarkers 632
Prognosis 632
Therapy 632
Suggested Readings 632
228: Skin Soft Tissue Tumors 633
229: SMARC-Deficient Sarcomas 636
Definition 636
Epidemiology and Presentation 637
Etiology and Predisposition 637
Pathology 637
Biomarkers 638
Prognosis 638
Therapy 638
Suggested Readings 638
230: SMARC-Deficient Thoracic Sarcoma 639
Definition 639
Epidemiology and Presentation 639
Pathology 639
Biomarkers 640
Prognosis 640
Therapy 640
Suggested Readings 640
231: SMARC-Deficient Uterine Sarcoma 642
Definition 642
Epidemiology and Presentation 642
Etiology and Predisposition 642
Pathology 643
Biomarkers 643
Prognosis 643
Therapy 643
Suggested Readings 644
232: Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP) 645
Definition 645
Epidemiology and Presentation 645
Pathology 645
Biomarkers 646
Prognosis 646
Therapy 646
Suggested Readings 646
233: Solitary Circumscribed Neuroma 648
Definition 648
Epidemiology and Presentation 648
Pathology 648
Biomarkers 649
Prognosis 649
Therapy 649
Suggested Readings 649
234: Solitary Fibrous Tumor 650
Definition 650
Epidemiology and Presentation 650
Pathology 651
Biomarkers 651
Prognosis 652
Therapy 652
Suggested Readings 653
235: Spindle Cell Hemangioma 654
Definition 654
Epidemiology and Presentation 654
Etiology and Predisposition 654
Pathology 655
Prognosis 655
Therapy 655
Suggested Readings 655
236: Spindle Cell Lipoma 656
Definition 656
Epidemiology and Presentation 656
Pathology 656
Biomarkers 657
Prognosis 657
Therapy 657
Suggested Readings 657
237: Spindle Cell/Sclerosing Rhabdomyosarcoma 658
Definition 658
Epidemiology and Presentation 658
Pathology 658
Biomarkers 659
Prognosis 659
Therapy 660
Suggested Readings 660
238: Spleen Soft Tissue Tumors 661
239: Superficial Angiomyxoma 662
Definition 662
Epidemiology and Presentation 662
Etiology and Predisposition 662
Pathology 663
Biomarkers 663
Prognosis 663
Therapy 663
Suggested Readings 663
240: Superficial Fibromatosis 664
241: Synovial Hemangioma 665
Definition 665
Epidemiology and Presentation 665
Pathology 665
Biomarkers 666
Prognosis 666
Therapy 666
Suggested Readings 666
242: Synovial Sarcoma 667
Definition 667
Epidemiology and Presentation 667
Etiology and Predisposition 668
Pathology 668
Biomarkers 669
Prognosis 670
Therapy 670
Suggested Readings 671
243: Tenosynovial Giant Cell Tumor 674
244: Triton Tumor 675
245: Tufted Hemangioma 676
Definition 676
Epidemiology and Presentation 676
Pathology 676
Biomarkers 677
Prognosis 677
Therapy 677
Suggested Readings 677
246: Undifferentiated Pleomorphic Sarcoma 678
Definition 678
Epidemiology and Presentation 678
Etiology and Predisposition 679
Pathology 679
Biomarkers 680
Prognosis 681
Therapy 681
Suggested Readings 681
247: Undifferentiated/Unclassified Sarcomas 683
248: Uterine Adenosarcoma 684
Definition 684
Epidemiology and Presentation 684
Pathology 684
Biomarkers 684
Prognosis 685
Therapy 685
Suggested Readings 685
249: Uterine Leiomyoma 686
Definition 686
Epidemiology and Presentation 686
Etiology and Predisposition 687
Pathology 687
Biomarkers 689
Prognosis 689
Therapy 689
Suggested Readings 690
250: Uterine Leiomyosarcoma 691
Definition 691
Epidemiology and Presentation 691
Pathology 691
Biomarkers 692
Prognosis 692
Therapy 692
Suggested Readings 693
251: Uterine Sarcomas 695
Definition 695
Epidemiology and Presentation 695
Prognosis 696
Therapy 696
Suggested Readings 697
252: Uterine Soft Tissue Tumors 698
253: Uterine Undifferentiated Sarcoma 700
Definition 700
Epidemiology and Presentation 700
Pathology 700
Biomarkers 701
Prognosis 701
Therapy 701
Suggested Readings 701
254: Venous Hemangioma 702
Definition 702
Epidemiology and Presentation 702
Pathology 702
Biomarkers 702
Prognosis 703
Therapy 703
Suggested Reading 703
255: Well-Differentiated Liposarcoma 704
Definition 704
Epidemiology and Presentation 704
Pathology 705
Biomarkers 705
Prognosis 706
Therapy 706
Suggested Readings 707
Index 708
| Erscheint lt. Verlag | 17.12.2020 |
|---|---|
| Zusatzinfo | XVII, 823 p. 7 illus., 5 illus. in color. |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Allgemeines / Lexika |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Chirurgie | |
| Schlagworte | Biomarkers • Chemotherapy • Diagnosis • epidemiology • genetic predisposition • immunotherapy • Pathology • prognosis • Soft Tissue Tumor • Surgery • therapy |
| ISBN-10 | 3-030-58710-X / 303058710X |
| ISBN-13 | 978-3-030-58710-9 / 9783030587109 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 17,2 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
